

A 2  
CONT

[Asn<sup>108</sup>] hTPO;  
[Asn<sup>117</sup>] hTPO;  
[Asn<sup>147</sup>] hTPO;  
[Asn<sup>153</sup>] hTPO;  
[Asn<sup>164</sup>] hTPO;  
[Asn<sup>193</sup>] hTPO;  
[Asn<sup>117</sup>, Asn<sup>147</sup>] hTPO;  
[Asn<sup>117</sup>, Asn<sup>164</sup>] hTPO;  
[Asn<sup>108</sup>, Asn<sup>147</sup>] hTPO;  
[Asn<sup>108</sup>, Asn<sup>164</sup>] hTPO;  
[Asn<sup>147</sup>, Asn<sup>164</sup>] hTPO;  
[Asn<sup>117</sup>, Asn<sup>147</sup>, Asn<sup>164</sup>] hTPO;  
[Asn<sup>108</sup>, Asn<sup>147</sup>, Asn<sup>164</sup>] hTPO;  
[Asn<sup>108</sup>, Asn<sup>117</sup>, Asn<sup>164</sup>] hTPO;  
[Asn<sup>157</sup>, Asn<sup>164</sup>] hTPO;  
[Asn<sup>162</sup>, Ser<sup>164</sup>] hTPO;  
[Asn<sup>162</sup>, Thr<sup>164</sup>] hTPO;  
[Asn<sup>153</sup>, Ser<sup>155</sup>, Asn<sup>164</sup>] hTPO;  
[Asn<sup>153</sup>, Thr<sup>155</sup>, Asn<sup>164</sup>] hTPO;  
[Asn<sup>159</sup>, Ser<sup>161</sup>, Asn<sup>164</sup>] hTPO;  
[Asn<sup>159</sup>, Thr<sup>161</sup>, Asn<sup>164</sup>] hTPO;  
[Asn<sup>166</sup>, Ser<sup>168</sup>] hTPO;  
[Asn<sup>166</sup>, Thr<sup>168</sup>] hTPO; and  
[Asn<sup>164</sup>, Asn<sup>168</sup>] hTPO.

2. (UNCHANGED) The human thrombopoietin derivative of claim 1 which is [Asn<sup>164</sup>] hTPO, [Asn<sup>193</sup>] hTPO, [Asn<sup>108</sup>, Asn<sup>117</sup>, Asn<sup>164</sup>] hTPO, or [Asn<sup>157</sup>, Asn<sup>164</sup>] hTPO.

A 3  
3. (AMENDED) A {R} recombinant gene encoding a human thrombopoietin derivative of claim 1.

4. (AMENDED) A {R} recombinant gene encoding a human thrombopoietin derivative of claim 2.

A3  
CONT  
5. (AMENDED) A {E}eukaryotic expression vector containing the recombinant gene of  
claim 3.

6. (UNCHANGED) The eukaryotic expression vector of claim 5 which is p40433, p40434,  
p40449, p40458, pD40433, pD40434, pD40449, or pD40458.

7. (UNCHANGED) Mammalian cell line CHO K-1/p40433 (Accession NO: KCTC  
0495BP) transfected with the expression vector p40433 of claim 6.

8. (UNCHANGED) Mammalian cell line CHO dhfr-/pD40434 (Accession NO: KCTC  
0630BP) transfected with the expression vector pD40434 of claim 6.

9. (UNCHANGED) Mammalian cell line CHO dhfr-/pD40449 (Accession NO: KCTC  
0631BP) transfected with the expression vector pD0449 of claim 6.

10. (UNCHANGED) Mammalian cell line CHO dhfr-/pD40458 (Accession NO: KCTC  
0632BP) transfected with the expression vector pD0458 of claim 6.

A4  
11. (AMENDED) A {P}process of preparing {the} a human thrombopoietin derivative {of  
claim 1 wherein} comprising culturing a mammalian cell line containing the recombinant  
gene of claim 3 {is used to obtain the} and obtaining a human thrombopoietin derivative  
{of claim 1} from the cultured mammalian cell line.

12. (AMENDED) A {P}pharmaceutical composition containing the human thrombopoietin  
derivative of claim 1 {which is used for the treatment of thrombocytopenia}.

REMARKS

Applicants have amended claims 1, 3-5 and 11-12, as indicated above, to clarify the language of the claims. These amendments are supported by the original application as filed, and introduce no new matter.